Guggenheim Initiates Coverage On Korsana Biosciences with Buy Rating, Announces Price Target of $70
Guggenheim analyst Yatin Suneja initiates coverage on Korsana Biosciences (NASDAQ:KRSA) with a Buy rating and announces Price Target of $70.
Share
Why It Matters
A big investment bank called Guggenheim says KRSA stock looks like a good buy. They think it could be worth around seventy dollars per share in the future.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.